新生源商务的模式精要中英文版.docVIP

新生源：实现生物医药的价值 Newsummit Biophama: Actualizing the value of biomedicine 加速新药成果产业化 Accelerate the industrialization of new drug achievement 加速生物产业资本化 Speed the capitalization of the bio-industry 加速科技资本国际化 Quicken the internationalization of science and technology capital 创新的活力 创业的激情 创优的机制（New Summit） 上海新生源集团于2001年，由以任军为首的创业团队以所获国家科技进步二等奖和上海首次实施科技成果转化政策的个人奖励30万元人民币注册创立。2008年新生源创新创业团队以中国公民身份获得上海市外汇管理局批准75号文件，完成红杉资本和 等国际投资基金4400万美金。 Innovative dynamism, entrepreneurial passion, mechanism for creating excellence Shanghai Newsummit Biopharma Group (Newsummit, NSB) was found in 2001, led by Ren Jun’s group, have achieved second prize of the national scientific and technological progress and in shanghai the implementing of scientific and technological achievements for the first time awarded 300,000 Yuan. In 2008, the innovative venture team, acted as Chinese citizenship, was approved by the Shanghai Foreign Exchange Administrative bureau No.75 document, completeing international investment funds like Sansar and Sequoia Capital which amounts 44 million U.S. dollars. Currently the management team will remain the largest shareholder, other investors include: Shanghai science and technology group, Fudan group and Guangming bloc etc. 产业集群战略：新药研发产业链式公共服务孵化平台（PCRD） 抓住天时地利人和，新生源实施以 “官产学研资” 联盟为核心的 “蓝海战略”，依托国家生物医药产业基地和高新技术园区，建设政府引导、企业主导，促进成果转化和产业化实施的新药研发产业链式公共服务孵化平台（PCRD, Platform Chain of Research Development）目前在上海新药中试产业化研究和（000 M2）江苏泰州新药研发公共服务平台（24000M2）和符合cGMP标准的新药CRO-CMO产业化基地（4000 M2）新药研发服务平台新药研究（000 M2）新药研发公共服务平台000 M2）。新生源初步形成高效集成、资源共享、集约配置、区域联动的网络化运营机制，实现中国生物医药产业资源优化整合（CRO，China Resource Organization）。Industrial Cluster Strategy: public service incubation platform chain of new drug RD industry NSB seized the opportune and applied the “Blue Ocean Strategy” as the core to unite government, enterprise, universities and institution. Relying on state biomedical industry base and high and new tech area, under deep cooperation framework with government, NSB formed new drug public